Tyrosine kinase mutations of JAK2 are rare events in AML but influence prognosis of patients with CBF-leukemias

被引：46

作者：

Illmer, Thomas ^{[1
]}

Schaich, Markus ^{[1
]}

Ehniger, Gerhard ^{[1
]}

Thiede, Christian ^{[1
]}

机构：

[1] Tech Univ Dresden, Med Klin & Poliklin 1, Univ Klinikum Carl Gustav Carus, D-01307 Dresden, Germany

来源：

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷 / 01期

关键词：

JAK2; AML; CBF-leukemias;

D O I：

10.3324/haematol.10489

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We investigated a large number of acute myeloid leukemia (AML) samples (n=959) for the presence of the JAK2 V617F mutation. We found a low incidence of the mutation in these AML samples (1%). JAK2 V617F mutations clustered in AML samples with an aberrant karyotype (p < 0.05). The incidence of JAK2 V617F in patients with a core binding factor (CBF) leukemia was 3.6% (p < 0.01). Moreover, JAK2 V617F mutations in CBF leukemias were associated with an aggressive clinical course with 80% of the patients relapsing.

引用

页码：137 / 138

页数：2

共 9 条

[1] Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7
Fröhling, S
Lipka, DB
Kayser, S
Scholl, C
Schlenk, RF
Döhner, H
Gilliland, DG
Levine, RL
Döhner, K
[J]. BLOOD, 2006, 107 (03) : 1242 - 1243
[2] A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C
Ugo, V
Le Couédic, JP
Staerk, J
Delhommeau, F
Lacout, C
Garçon, L
Raslova, H
Berger, R
Bennaceur-Griscelli, A
Villeval, JL
Constantinescu, SN
Casadevall, N
Vainchenker, W
[J]. NATURE, 2005, 434 (7037) : 1144 - 1148
[3] Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha
Jones, AV
Silver, RT
Waghorn, K
Curtis, C
Kreil, S
Zoi, K
Hochhaus, A
Oscier, D
Metzgeroth, G
Lengfelder, E
Reiter, A
Chase, AJ
Cross, NCP
[J]. BLOOD, 2006, 107 (08) : 3339 - 3341
[4] The JAK2 V617F mutation in de novo acute myelogenous leukemias
Lee, JW
Kim, YG
Soung, YH
Han, KJ
Kim, SY
Rhim, HS
Min, WS
Nam, SW
Park, WS
Lee, JY
Yoo, NJ
Lee, SH
[J]. ONCOGENE, 2006, 25 (09) : 1434 - 1436
[5] Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
Levine, RL
Wadleigh, M
Cools, J
Ebert, BL
Wernig, G
Huntly, BJP
Boggon, TJ
Wlodarska, L
Clark, JJ
Moore, S
Adelsperger, J
Koo, S
Lee, JC
Gabriel, S
Mercher, T
D'Andrea, A
Fröhling, S
Döhner, K
Marynen, P
Vandenberghe, P
Mesa, RA
Tefferi, A
Griffin, JD
Eck, MJ
Sellers, WR
Meyerson, M
Golub, TR
Lee, SJ
Gilliland, DG
[J]. CANCER CELL, 2005, 7 (04) : 387 - 397
[6] Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells
Ruchatz, H
Coluccia, AML
Stano, P
Marchesi, E
Gambacorti-Passerini, C
[J]. EXPERIMENTAL HEMATOLOGY, 2003, 31 (04) : 309 - 315
[7] Mutations in ras proto-oncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukaemia
Schaich, M
Ritter, M
Illmer, T
Lisske, P
Thiede, C
Schäkel, U
Mohr, B
Ehninger, G
Neubauer, A
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2001, 112 (02) : 300 - 307
[8] Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia:: association with FAB subtypes and identification of subgroups with poor prognosis
Thiede, C
Steudel, C
Mohr, B
Schaich, M
Schäkel, U
Platzbecker, U
Wermke, M
Bornhäuser, M
Ritter, M
Neubauer, A
Ehninger, G
Illmer, T
[J]. BLOOD, 2002, 99 (12) : 4326 - 4335
[9] Activated Jak2 with the V617F point mutation promotes G1/S phase transition
Walz, Christoph
Crowley, Brian J.
Hudon, Heidi E.
Gramlich, Jessica L.
Neuberg, Donna S.
Podar, Klaus
Griffin, James D.
Sattler, Martin
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (26) : 18177 - 18183

← 1 →